UPL Limited
Financial trend (81/100) does the heavy lifting; momentum (41/100) is the drag.
Fair valueSolvency riskUPL Limited earns a Sell from StocksWizard, with a blended score of 40/100. At ₹609.15 it trades below our blended DCF and relative-multiples fair value of ₹703.51, about 15% upside to that estimate — we read it as undervalued by 15%. On 26.8x trailing earnings it sits pricier than the Basic Materials median of about 22.2x. The price is about 24% below its 52-week high of ₹797.63 and 9% above the low of ₹559.63. Financial health scores 13/100, in the distress band on the Altman Z-score, with a Piotroski F-score of 6/9. The average analyst target of ₹760.94 implies about 25% upside across 17 analysts. It clears 5 of 13 investability checks, with durability 41, valuation 57 and momentum 41 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹562.81.
Analyst views
1-year price
EOD · 2026-07-2952-week range
-23.63% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell40Piotroski F-score 6/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 5.6%
- Fail: Low debt (D/E < 0.5): 0.57x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 18%
- Pass: Earnings growing: 33%
- Fail: Net margin ≥ 10%: 3.7%
- Fail: Current ratio > 1.5: 1.22
- Pass: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Fail: Altman Z in safe zone: Z 1.51
- Fail: Piotroski ≥ 7: 6/9
Quarterly results
Annual financials
Shareholding
- Promoter33.8%
- Institutions42.4%
- Public & other23.8%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Opportunities
- Earnings growing (33% YoY).
- Revenue growing (18% YoY).
Bear case
Weaknesses
- Low return on equity (5.6%).
- Price below its 200-day moving average (downtrend).
Threats
- Balance-sheet stress — Altman Z 1.51.
About UPL Limited
UPL Limited manufactures and sells pesticides, insecticides, and micronutrients across India, Brazil, the United States, the United Kingdom, and other markets. The company operates three segments: Crop Protection, Seeds, and Non-Agro, offering herbicides, fungicides, insecticides, acaricides, seed treatment products, adjuvants, bio-solutions, public health products, fumigants, and soil and water technologies.
UPL Limited — frequently asked questions
Is UPL Limited a buy, hold or sell?
StocksWizard currently rates UPL Limited (UPL) a Sell, based on a blended score of 40/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is UPL Limited's fair value?
Our blended DCF and relative-valuation model estimates UPL Limited's fair value at about ₹703.51, versus a current price of ₹609.15 — roughly 15% upside. On that basis the stock looks undervalued by 15%.
Is UPL Limited financially healthy?
UPL Limited scores 13/100 on our financial-health model, placing it in the distress band on the Altman Z-score, with a Piotroski F-score of 6/9.
How has UPL Limited's share price performed?
UPL Limited is down 4% over three months, and last traded at ₹609.15. Past performance doesn't predict future returns.
More in Basic Materials
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.